RYTM — Rhythm Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $5.18bn
- $4.90bn
- $189.76m
Annual cashflow statement for Rhythm Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -69.6 | -181 | -185 | -261 | -197 |
| Depreciation | |||||
| Non-Cash Items | -79.4 | 25.7 | 42 | 135 | 80.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.9 | -19.7 | 4.81 | 10.6 | -0.968 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -146 | -173 | -136 | -114 | -116 |
| Capital Expenditures | -0.434 | -0.281 | -0.047 | — | -0.953 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -61.7 | 28.3 | -5.62 | -48.2 | -136 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -62.2 | 28 | -5.67 | -48.2 | -137 |
| Financing Cash Flow Items | — | — | — | 8.9 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 166 | 214 | 74.4 | 191 | 218 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -41.7 | 68.4 | -67.6 | 29.2 | -34.8 |